Biotech Values

[genisi]

BAX/IVIG Alzheimer's

This phase III trial of Gammagard is in mild-to-moderate Alzheimer's (http://clinicaltrials.gov/ct2/show/NCT00818662?term=Gammagard++alzheimer&phase=2&rank=2 ), which now we know is too late (better shot with the mild subgroup but will be too small), so low chance to be able to show impact on disease progression (cognitive and functional). The trial was not stopped for futility, so it probably has at least 20% chance of success.